Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 6.39
NAVB's Cash-to-Debt is ranked lower than
60% of the 983 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAVB: 6.39 )
Ranked among companies with meaningful Cash-to-Debt only.
NAVB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 2.29 Max: No Debt
Current: 6.39
Equity-to-Asset 0.66
NAVB's Equity-to-Asset is ranked lower than
52% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAVB: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
NAVB' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.42  Med: 0.45 Max: 0.95
Current: 0.66
-7.42
0.95
Piotroski F-Score: 6
Altman Z-Score: -8.23
Beneish M-Score: 2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -15.72
NAVB's Operating Margin % is ranked higher than
64% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAVB: -15.72 )
Ranked among companies with meaningful Operating Margin % only.
NAVB' s Operating Margin % Range Over the Past 10 Years
Min: -35429.11  Med: -290.2 Max: -10.12
Current: -15.72
-35429.11
-10.12
Net Margin % 420.48
NAVB's Net Margin % is ranked higher than
98% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAVB: 420.48 )
Ranked among companies with meaningful Net Margin % only.
NAVB' s Net Margin % Range Over the Past 10 Years
Min: -36907.59  Med: -312.08 Max: 938.63
Current: 420.48
-36907.59
938.63
ROA % 483.33
NAVB's ROA % is ranked higher than
100% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAVB: 483.33 )
Ranked among companies with meaningful ROA % only.
NAVB' s ROA % Range Over the Past 10 Years
Min: -502.64  Med: -136.06 Max: 483.33
Current: 483.33
-502.64
483.33
ROC (Joel Greenblatt) % -186.22
NAVB's ROC (Joel Greenblatt) % is ranked higher than
57% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. NAVB: -186.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAVB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8007.05  Med: -1014.19 Max: -117.97
Current: -186.22
-8007.05
-117.97
3-Year Revenue Growth Rate 150.20
NAVB's 3-Year Revenue Growth Rate is ranked higher than
96% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAVB: 150.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAVB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -80.2  Med: 5.65 Max: 344.8
Current: 150.2
-80.2
344.8
3-Year EBITDA Growth Rate -67.20
NAVB's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NAVB: -67.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAVB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -24 Max: 141.3
Current: -67.2
0
141.3
3-Year EPS without NRI Growth Rate -36.40
NAVB's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 553 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAVB: -36.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAVB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5 Max: 112.9
Current: -36.4
0
112.9
GuruFocus has detected 6 Warning Signs with Navidea Biopharmaceuticals Inc $NAVB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAVB's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:OTCPK:SVACD, NAS:NVET, OTCPK:NURPF, NAS:ARQL, OTCPK:FENCF, NAS:BLRX, NAS:MTFB, OTCPK:PTGEF, AMEX:SYN, NAS:MRTX, NAS:NTEC, NAS:VSTM, NAS:GTXI, NAS:BCLI, OTCPK:RNUGF, NAS:KALV, NAS:VCEL, OTCPK:ARTH, NAS:APEN, NAS:GLMD » details
Traded in other countries:NO1.Germany,
Headquarter Location:USA
Navidea Biopharmaceuticals Inc is a precision medicines company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents.

Navidea Biopharmaceuticals is a biotechnology company specialized in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products, are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.

Ratios

vs
industry
vs
history
PE Ratio 1.15
NAVB's PE Ratio is ranked higher than
97% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 30.85 vs. NAVB: 1.15 )
Ranked among companies with meaningful PE Ratio only.
NAVB' s PE Ratio Range Over the Past 10 Years
Min: 0.98  Med: 26.52 Max: 123.21
Current: 1.15
0.98
123.21
Price-to-Owner-Earnings 1.38
NAVB's Price-to-Owner-Earnings is ranked higher than
97% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 35.17 vs. NAVB: 1.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NAVB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.18  Med: 22.43 Max: 172.5
Current: 1.38
1.18
172.5
PB Ratio 3.95
NAVB's PB Ratio is ranked higher than
52% of the 888 Companies
in the Global Biotechnology industry.

( Industry Median: 3.78 vs. NAVB: 3.95 )
Ranked among companies with meaningful PB Ratio only.
NAVB' s PB Ratio Range Over the Past 10 Years
Min: 3.36  Med: 35.15 Max: 152.86
Current: 3.95
3.36
152.86
PS Ratio 4.56
NAVB's PS Ratio is ranked higher than
74% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.91 vs. NAVB: 4.56 )
Ranked among companies with meaningful PS Ratio only.
NAVB' s PS Ratio Range Over the Past 10 Years
Min: 1.86  Med: 15.5 Max: 3570
Current: 4.56
1.86
3570
Price-to-Free-Cash-Flow 1.22
NAVB's Price-to-Free-Cash-Flow is ranked higher than
98% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 27.50 vs. NAVB: 1.22 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NAVB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.03  Med: 1.44 Max: 31.74
Current: 1.22
1.03
31.74
Price-to-Operating-Cash-Flow 1.22
NAVB's Price-to-Operating-Cash-Flow is ranked higher than
99% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 24.15 vs. NAVB: 1.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NAVB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.03  Med: 1.44 Max: 31.74
Current: 1.22
1.03
31.74
Current Ratio 2.18
NAVB's Current Ratio is ranked lower than
72% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAVB: 2.18 )
Ranked among companies with meaningful Current Ratio only.
NAVB' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 3.02 Max: 21
Current: 2.18
0.11
21
Quick Ratio 2.18
NAVB's Quick Ratio is ranked lower than
68% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAVB: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
NAVB' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 2.81 Max: 20.67
Current: 2.18
0.1
20.67
Days Inventory 125.35
NAVB's Days Inventory is ranked higher than
52% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. NAVB: 125.35 )
Ranked among companies with meaningful Days Inventory only.
NAVB' s Days Inventory Range Over the Past 10 Years
Min: 98.26  Med: 164.82 Max: 1386.56
Current: 125.35
98.26
1386.56
Days Sales Outstanding 147.13
NAVB's Days Sales Outstanding is ranked lower than
83% of the 627 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NAVB: 147.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAVB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.77  Med: 73.51 Max: 1211.54
Current: 147.13
9.77
1211.54
Days Payable 497.79
NAVB's Days Payable is ranked higher than
94% of the 433 Companies
in the Global Biotechnology industry.

( Industry Median: 55.32 vs. NAVB: 497.79 )
Ranked among companies with meaningful Days Payable only.
NAVB' s Days Payable Range Over the Past 10 Years
Min: 88.95  Med: 339.91 Max: 2654.74
Current: 497.79
88.95
2654.74

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.60
NAVB's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. NAVB: -4.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAVB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -40.1  Med: -11.55 Max: -0.7
Current: -4.6
-40.1
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 53.00
NAVB's Price-to-Net-Cash is ranked lower than
93% of the 532 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. NAVB: 53.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NAVB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.27  Med: 16.07 Max: 166
Current: 53
2.27
166
Price-to-Net-Current-Asset-Value 8.83
NAVB's Price-to-Net-Current-Asset-Value is ranked lower than
55% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. NAVB: 8.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NAVB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.85  Med: 10 Max: 275
Current: 8.83
0.85
275
Price-to-Tangible-Book 4.08
NAVB's Price-to-Tangible-Book is ranked higher than
59% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. NAVB: 4.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NAVB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.69  Med: 7.33 Max: 144.62
Current: 4.08
0.69
144.62
Price-to-Median-PS-Value 0.29
NAVB's Price-to-Median-PS-Value is ranked higher than
89% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NAVB: 0.29 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NAVB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.59 Max: 141.5
Current: 0.29
0.04
141.5
Earnings Yield (Greenblatt) % -3.70
NAVB's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. NAVB: -3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAVB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -22.1  Med: -7.3 Max: -1
Current: -3.7
-22.1
-1

More Statistics

Revenue (TTM) (Mil) $17.83
EPS (TTM) $ 0.46
Beta-0.97
Short Percentage of Float8.28%
52-Week Range $0.26 - 1.16
Shares Outstanding (Mil)161.90
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 

More From Other Websites
Navidea Enters Exclusive License and Distribution Agreement For India with Sayre Therapeutics Jun 20 2017
Navidea getting new revenue source as cancer diagnostic aid launches in Europe Jun 12 2017
Navidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® in Europe Jun 12 2017
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : June 9, 2017 Jun 09 2017
Navidea Biopharmaceuticals to Present at the 7th Annual LD Micro Invitational Investor Conference Jun 01 2017
Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 May 26 2017
Edited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT May 18 2017
Navidea pays former CEO $618,000 after losing arbitration over his firing May 18 2017
Navidea posts 1Q profit May 09 2017
Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results May 09 2017
Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences Apr 25 2017
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 19, 2017 Apr 19 2017
Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4,... Apr 04 2017
Navidea halved losses in 2016, projects positive cash flow in 2017 Mar 30 2017
Navidea reports 4Q loss Mar 29 2017
Navidea Provides Corporate Update and Reports Full Year 2016 Results Mar 29 2017
Why Navidea can recover no more than $12M if it wins against ex-lender in court Mar 13 2017
Navidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens Mar 06 2017
Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health Mar 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}